.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,563,613

« Back to Dashboard

Claims for Patent: 8,563,613

Title:Diclofenac topical formulation
Abstract: The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.
Inventor(s): Kisak; Ed (San Diego, CA), Singh; Jagat (Toronto, CA)
Assignee: Nuvo Research Inc. (Mississauga, Ontario, CA)
Application Number:13/564,688
Patent Claims: 1. A topical formulation comprising: (i) 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, or 5.0% w/w and all fractions in between, diclofenac sodium; (ii) 30-60% w/w DMSO; (iii) 1-15% w/w propylene glycol; (iv) 1-30% w/w ethanol; (v) optionally glycerine; (vi) water; (vii) at least one thickening agent selected from the group consisting of a cellulose polymer, a carbomer polymer, a carbomer derivative, a cellulose derivative, and mixtures thereof; wherein the topical formulation has a viscosity of 500-5000 centipoise; and wherein the formulation degrades by less than 1% over 6 months.

2. The topical formulation of claim 1, wherein the concentration of diclofenac sodium is a member selected from the group consisting of 1%, 1.5% and 2% w/w, and all fractions in between.

3. The topical formulation of claim 1, wherein the concentration of DMSO is about 40% to about 50% w/w.

4. The topical formulation of claim 3, wherein the concentration of DMSO is a member selected from the group consisting of 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% and 50% w/w, and all fractions in between.

5. The topical formulation of claim 1, wherein the concentration of ethanol is present at 23-29% w/w.

6. The topical formulation of claim 1, wherein the at least one thickening agent is selected from the group consisting of a carbomer polymer, a carbomer derivative and mixtures thereof.

7. The topical formulation of claim 6, wherein the at least one thickening agent is selected from the group consisting of carbopol 971, carbopol 981, carbopol 941, carbopol 1342 and ultrez 10.

8. The topical formulation of claim 6, wherein glycerine is present.

9. The topical formulation of claim 1, wherein the at least one thickening agent is selected from the group consisting of a cellulose polymer, a cellulose derivative, and mixtures thereof.

10. The topical formulation of claim 9, wherein the at least one thickening agent is hydroxypropyl cellulose.

11. The topical formulation of claim 10, wherein the formulation comprises: (i) 1.5, 2.0, 2.5, 3.0, 3.5, 4.0 or 5.0% w/w, and all fractions in between, of diclofenac sodium; (ii) 40-50% w/w of DMSO; (iii) 23-29% w/w of ethanol; and (iv) 10-12% w/w of propylene glycol.

12. The topical formulation of claim 11, wherein the concentration of diclofenac sodium is a member selected from the group consisting of 1.5% and 2% w/w, and all fractions in between.

13. The topical formulation of claim 11, wherein the concentration of DMSO is a member selected from the group consisting of 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% and 50% w/w, and all fractions in between.

14. The topical formulation of claim 11, wherein the concentration of ethanol is present at 26.5% w/w.

15. A method for treating pain in a subject suffering from pain, said method comprising the topical administration of a formulation comprising: (i) diclofenac sodium present at 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, or 5.0% w/w and all fractions in between; (ii) DMSO present at 30-60% w/w; (iii) ethanol present at 1-30% w/w; (iv) propylene glycol present at 1-15% w/w; (v) optionally glycerine; (vi) a thickening agent, wherein said thickening agent is selected from the group consisting of cellulose polymers, carbomer polymers, a carbomer derivative, a cellulose derivative and mixtures thereof; and (vii) water; wherein the formulation has a viscosity of 500-5000 centipoise; and wherein the formulation degrades by less than 1% over 6 months.

16. The method of claim 15, wherein the concentration of diclofenac sodium is a member selected from the group consisting of 1%, 1.5% and 2% w/w, and all fractions in between.

17. The method of claim 15, wherein the concentration of DMSO is about 40% to about 50% w/w.

18. The method of claim 17, wherein the concentration of DMSO is a member selected from the group consisting of 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% and 50% w/w, and all fractions in between.

19. The method of claim 15, wherein the concentration of ethanol is present at 23-29% w/w.

20. The method of claim 15, wherein the at least one thickening agent is selected from the group consisting of a carbomer polymer, a carbomer derivative and mixtures thereof.

21. The method of claim 20, wherein glycerine is present.

22. The method of claim 15, wherein the at least one thickening agent is selected from the group consisting of a cellulose polymer, a cellulose derivative, and mixtures thereof.

23. The method of claim 22, wherein the at least one thickening agent is hydroxypropyl cellulose.

24. The formulation of claim 1, wherein the formulation degrades by less than 0.5% over 6 months.

25. The formulation of claim 1, wherein the formulation degrades by less than 0.2% over 6 months.

26. The formulation of claim 1, wherein the formulation degrades by less than 1% over 6 months at room temperature.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc